Redhill Biopharma Ltd (RDHL) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $0.56 (-5.36%), Market cap $0.00B, 52-week low–high $0.74 ~ $2.52.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Cro
Financial statements, price targets, institutional (13F) holdings and related news for Redhill Biopharma Ltd are updated in real time on BlackAll Trade.
Redhill Biopharma Ltd trades at $0.56 (-5.36%). Real-time quotes and charts are available on BlackAll Trade.
Redhill Biopharma Ltd has a market cap of about $0.00B.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. py